The Wedelolactone Derivative Inhibits Estrogen Receptor-Mediated Breast, Endometrial, and Ovarian Cancer Cells Growth
Figure 3
IC50 of BTB in different breast, endometrial, and ovary cancer cell lines. We determine the cell half-inhibition (IC50) of BTB in MCF-7, Ishikawa, SKOV-3, MDA-MB-231, HEC-1-A, and OVCA429 cells. Cells were seeded on 24-well plates in medium with 10% FBS for 24 hr. Medium was then refreshed to phenol red free DMEM medium with 5% CS-FBS for another 24 hr, and cells were treated with serial concentrations of BTB with or without 10 nM E2 for 2 days. Cells growth and IC50 value were determined by MTT assay and confirmed by direct cell number count. The concentration of BTB treatment that leads to 50% inhibition of cell growth is determined as IC50. Data represent mean ± SD collected from three independent experiments.
